Entrada receives authorization in the United Kingdom to start a Phase 1/2 Duchenne trial skipping exon 45

Entrada receives authorization in the United Kingdom to start a Phase 1/2 Duchenne trial skipping exon 45

Entrada trial skipping exon 45 CureDuchenne provided early funding to Entrada Therapeutics, who has announced that they received authorization in the United Kingdom (UK) to initiate a Phase 1/2 multiple ascending dose clinical trial in individuals with Duchenne amenable to skipping exon 45.  They plan to start that trial in Q3 2025.  This is the second clinical exon-skipping program for Entrada, who has authorization for exon 44 skipping trials …